Josh Mandel-Brehm
Director/Board Member at PROMIS NEUROSCIENCES, INC.
Net worth: - $ as of 2024-05-30
Network origin in Josh Mandel-Brehm first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Biotechnology | 17 | |
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022.
12
| Holding Company | Biotechnology | 12 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Josh Mandel-Brehm via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
PFIZER, INC. | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
GERON CORPORATION | Biotechnology | Investor Relations Contact Corporate Officer/Principal | |
VERNALIS | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Operating Officer Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
IRONWOOD PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Founder Director/Board Member | |
DNIB UNWIND INC | Biotechnology | Director/Board Member Director/Board Member | |
KinDex Pharmaceuticals, Inc.
KinDex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kindex Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing of novel therapeutics for the treatment of metabolic. The company is headquartered in Boston, MA. | Biotechnology | Director/Board Member Chief Executive Officer | |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director of Finance/CFO Director/Board Member | |
Polaris Growth Management LLC
Polaris Growth Management LLC Investment ManagersFinance Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham. | Investment Managers | Private Equity Investor Private Equity Investor | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder Private Equity Analyst | |
McGill University | College/University | Undergraduate Degree Doctorate Degree | |
Massachusetts Institute of Technology | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
Indiana University | College/University | Undergraduate Degree Undergraduate Degree | |
University of Alberta | College/University | Undergraduate Degree Corporate Officer/Principal | |
University of Toronto | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member | |
Technical University of Denmark | College/University | Corporate Officer/Principal | |
Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Whitehead Institute for Biomedical Research provides research and technology services. Its services include biomedical, genomics, and genetics for students. The company was founded by Edwin C. Whitehead in 1982 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Medical Specialties | Director of Finance/CFO Director/Board Member | |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
GENEXINE, INC. | Biotechnology | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
Bankinvest Biomedical Venture
Bankinvest Biomedical Venture Investment ManagersFinance Bankinvest Biomedical Venture provides investment services. The company was founded in 1998 and is headquartered in Copenhagen, Denmark. | Investment Managers | Corporate Officer/Principal | |
IMMUNE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Operating Officer | |
SYROS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Founder Director of Finance/CFO | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Eloxx Pharmaceuticals Ltd.
Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
Olivo Laboratories LLC
Olivo Laboratories LLC Medical/Nursing ServicesHealth Services Olivo Laboratories LLC provides solutions to skin-related medical problems through proprietary biomaterials technologies. Its platform technology consists of a tunable polysiloxane-based material that mimics youthful skin and can be engineered to provide a variety of targeted properties, including elasticity, breathability, invisibility, water resistance, protection. The company was founded by Robert S. Langer Jr. and Richard Rox Anderson and is headquartered in Cambridge, MA. | Medical/Nursing Services | Chief Executive Officer Chief Executive Officer | |
ELOXX PHARMACEUTICALS, INC. | Biotechnology | Director of Finance/CFO Director/Board Member Founder | |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Virtua LLC | Founder Founder | ||
CYCLERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Dewpoint Therapeutics, Inc.
Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Founder | |
Volastra Therapeutics, Inc.
Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member Director/Board Member | |
I-Mab Biopharma US Ltd. | Corporate Officer/Principal | ||
Muna Therapeutics ApS
Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member Chief Operating Officer | |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Paratus Sciences Corp. is an American company that focuses on unlocking the secrets of bat biology. The company's main goal is to elucidate novel insights and identify new therapeutic targets. The company was founded by Thomas Zwaka, Richard Young, Paul Matsudaira. The CEO is Amir H. Nashat. | Biotechnology | Chairman Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistics
International
United States | 30 |
Netherlands | 7 |
Denmark | 6 |
Canada | 5 |
Switzerland | 3 |
Sectoral
Health Technology | 30 |
Consumer Services | 8 |
Finance | 7 |
Commercial Services | 4 |
Health Services | 3 |
Operational
Director/Board Member | 298 |
Corporate Officer/Principal | 79 |
Independent Dir/Board Member | 55 |
Chief Executive Officer | 48 |
Director of Finance/CFO | 48 |
Most connected contacts
Insiders | |
---|---|
Daniel Geffken | 53 |
Amir Nashat | 51 |
Amy Schulman | 45 |
Martijn Kleijwegt | 33 |
Rémi Droller | 29 |
Steven Holtzman | 28 |
Luc Dochez | 26 |
Shaan Gandhi | 22 |
William Wyman | 21 |
Michael Higgins | 20 |
Jorge Conde | 18 |
Klaus Breiner | 16 |
Gail Farfel | 15 |
Neil Warma | 15 |
Anders Hinsby | 14 |
- Stock Market
- Insiders
- Josh Mandel-Brehm
- Company connections